Back to Search
Start Over
Biotechnology in China - regulation, investment, and delayed commercialization.
- Source :
-
GM crops & food [GM Crops Food] 2022 Dec 31; Vol. 13 (1), pp. 86-96. - Publication Year :
- 2022
-
Abstract
- China has been investing heavily in biotechnology to increase agricultural productivity. While a number of Chinese developed GM crops have cleared the required scientific hurdles - some more than a decade ago - commercialization has not been approved. The regulatory regime for GMOs in China is relatively less well understood than that of the US or the EU. This paper provides a systematic overview of China's regulatory regime, R&D investment and delayed commercialization decisions on biotechnology over the last 40 years and draws some conclusions regarding the likelihood of the commercialization for major GM crops in the future.
Details
- Language :
- English
- ISSN :
- 2164-5701
- Volume :
- 13
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- GM crops & food
- Publication Type :
- Academic Journal
- Accession number :
- 35506348
- Full Text :
- https://doi.org/10.1080/21645698.2022.2068336